1. 曼宁和内皮尔顾问公司在第二季度增加了2,416,672股阿斯特拉泽内卡的投资. 1. Manning & Napier Advisors LLC increased AstraZeneca investment by 2,416,672 shares in Q2.

曼宁和纳皮尔顾问公司在第二季度增加了2,416,672股价值188.48万美元的阿斯特拉泽内卡 (AZN) 投资,占投资组合的2.1%,排名第10大持股. Manning & Napier Advisors LLC boosted its AstraZeneca (AZN) investment by 2,416,672 shares worth $188.48M in Q2, comprising 2.1% of the portfolio and ranking as the 10th largest holding. AstraZeneca报告Q2 EPS为0.99美元,高于分析师的估计,为各种疾病提供一系列处方药。 AstraZeneca reported Q2 EPS of $0.99, above analyst estimates, and offers a range of prescription medicines for various illnesses. 分析员保持“Buy”评级,平均价格目标是88美元。 Analysts maintain a "Buy" rating with an average price target of $88.